Infliximab safety experience: data from clinical trials in patients with psoriatic disease

被引：0
|
作者：
Guzzo, C. [1 ]
Gordon, K. [2 ]
Nestle, F. O. [3 ]
Li, S. [1 ]
机构：
[1] Centocor Res & Dev Inc, Malvern, PA USA
[2] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[3] Kings Coll London, Sch Med, London WC2R 2LS, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：417 / 417
页数：1
相关论文
共 50 条
  • [1] Infliximab safety experience: Data from clinical trials in patients with psoriatic disease
    Gordon, KB
    Nestle, FO
    Guzzo, C
    Li, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB220 - AB220
  • [2] Infliximab safety experience: Data from clinical trials in patients with psoriatic disease
    Gordon, Kenneth B.
    Nestle, Frank O.
    Guzzo, Cynthia
    Li, Shu
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (07) : 1823 - 1823
  • [3] Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials
    Gordon, Kenneth B.
    Blauvelt, Andrew
    Bachelez, Herve
    Coates, Laura C.
    Van den Bosch, Filip E.
    Kaplan, Blair
    Koetse, Willem
    Ashley, Doug G.
    Lippe, Ralph
    Sinvhal, Ranjeeta
    Papp, Kim A.
    DERMATOLOGY AND THERAPY, 2024, 14 (09) : 2523 - 2538
  • [4] Risankizumab Long-Term Safety in Patients With Psoriatic Disease: Integrated Interval Analyses From Psoriasis and Psoriatic Arthritis Clinical Trials
    Gordon, Kenneth
    Blauvelt, Andrew
    Coates, Laura C.
    Kaplan, Blair
    Koetse, Willem
    Drogaris, Leonidas
    Sinvhal, Ranjeeta
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB219 - AB219
  • [5] Infusion reactions in infliximab treated patients: Data from psoriasis clinical trials
    Leonardi, C.
    Guzzo, C.
    Reich, K.
    Li, S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB177 - AB177
  • [6] 2-year data: Infliximab maintains clinical response in psoriatic arthritis patients-data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni, CE
    Kavanaugh, A
    Kirkham, B
    Tutuncu, ZN
    Burmester, G
    Schneider, U
    Furst, DE
    Moliter, J
    Keystone, EC
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, D
    Weisman, M
    Kalden, JR
    Smolen, JS
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S209 - S209
  • [7] Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials
    Valenti, Mario
    Costanzo, Antonio
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (03) : 316 - 317
  • [8] Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
    Genovese, Mark C.
    Mysler, Eduardo
    Tomita, Tetsuya
    Papp, Kim A.
    Salvarani, Carlo
    Schwartzman, Sergio
    Gallo, Gaia
    Patel, Himanshu
    Lisse, Jeffrey R.
    Kronbergs, Andris
    Leage, Soyi Liu
    Adams, David H.
    Xu, Wen
    Marzo-Ortega, Helena
    Lebwohl, Mark G.
    RHEUMATOLOGY, 2020, 59 (12) : 3834 - 3844
  • [9] Review article: safety of infliximab in clinical trials
    Hanauer, SB
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 : 16 - 22
  • [10] Long-term safety of risankizumab in patients with psoriatic disease: Findings from integrated analyses of 17 clinical trials in psoriasis and 4 in psoriatic arthritis
    Gordon, Kenneth B.
    Blauvelt, Andrew
    Bachelez, Herve
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB78 - AB78
12345